High-potency ligands for DREADD imaging and activation in rodents and monkeys

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

High-potency ligands for DREADD imaging and activation in rodents and monkeys. / Bonaventura, Jordi; Eldridge, Mark A.G.; Hu, Feng; Gomez, Juan L.; Sanchez-Soto, Marta; Abramyan, Ara M.; Lam, Sherry; Boehm, Matthew A.; Ruiz, Christina; Farrell, Mitchell R.; Moreno, Andrea; Galal Faress, Islam Mustafa; Andersen, Niels; Lin, John Y.; Moaddel, Ruin; Morris, Patrick J.; Shi, Lei; Sibley, David R.; Mahler, Stephen V.; Nabavi, Sadegh; Pomper, Martin G.; Bonci, Antonello; Horti, Andrew G.; Richmond, Barry J.; Michaelides, Michael.

I: Nature Communications, Bind 10, Nr. 1, 4627, 01.12.2019.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Bonaventura, J, Eldridge, MAG, Hu, F, Gomez, JL, Sanchez-Soto, M, Abramyan, AM, Lam, S, Boehm, MA, Ruiz, C, Farrell, MR, Moreno, A, Galal Faress, IM, Andersen, N, Lin, JY, Moaddel, R, Morris, PJ, Shi, L, Sibley, DR, Mahler, SV, Nabavi, S, Pomper, MG, Bonci, A, Horti, AG, Richmond, BJ & Michaelides, M 2019, 'High-potency ligands for DREADD imaging and activation in rodents and monkeys', Nature Communications, bind 10, nr. 1, 4627. https://doi.org/10.1038/s41467-019-12236-z

APA

Bonaventura, J., Eldridge, M. A. G., Hu, F., Gomez, J. L., Sanchez-Soto, M., Abramyan, A. M., Lam, S., Boehm, M. A., Ruiz, C., Farrell, M. R., Moreno, A., Galal Faress, I. M., Andersen, N., Lin, J. Y., Moaddel, R., Morris, P. J., Shi, L., Sibley, D. R., Mahler, S. V., ... Michaelides, M. (2019). High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications, 10(1), [4627]. https://doi.org/10.1038/s41467-019-12236-z

CBE

Bonaventura J, Eldridge MAG, Hu F, Gomez JL, Sanchez-Soto M, Abramyan AM, Lam S, Boehm MA, Ruiz C, Farrell MR, Moreno A, Galal Faress IM, Andersen N, Lin JY, Moaddel R, Morris PJ, Shi L, Sibley DR, Mahler SV, Nabavi S, Pomper MG, Bonci A, Horti AG, Richmond BJ, Michaelides M. 2019. High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications. 10(1):Article 4627. https://doi.org/10.1038/s41467-019-12236-z

MLA

Vancouver

Bonaventura J, Eldridge MAG, Hu F, Gomez JL, Sanchez-Soto M, Abramyan AM o.a. High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications. 2019 dec 1;10(1). 4627. https://doi.org/10.1038/s41467-019-12236-z

Author

Bonaventura, Jordi ; Eldridge, Mark A.G. ; Hu, Feng ; Gomez, Juan L. ; Sanchez-Soto, Marta ; Abramyan, Ara M. ; Lam, Sherry ; Boehm, Matthew A. ; Ruiz, Christina ; Farrell, Mitchell R. ; Moreno, Andrea ; Galal Faress, Islam Mustafa ; Andersen, Niels ; Lin, John Y. ; Moaddel, Ruin ; Morris, Patrick J. ; Shi, Lei ; Sibley, David R. ; Mahler, Stephen V. ; Nabavi, Sadegh ; Pomper, Martin G. ; Bonci, Antonello ; Horti, Andrew G. ; Richmond, Barry J. ; Michaelides, Michael. / High-potency ligands for DREADD imaging and activation in rodents and monkeys. I: Nature Communications. 2019 ; Bind 10, Nr. 1.

Bibtex

@article{d5a6e1a07d6642ba8e4fa0f9ea9a11a7,
title = "High-potency ligands for DREADD imaging and activation in rodents and monkeys",
abstract = "Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a popular chemogenetic technology for manipulation of neuronal activity in uninstrumented awake animals with potential for human applications as well. The prototypical DREADD agonist clozapine N-oxide (CNO) lacks brain entry and converts to clozapine, making it difficult to apply in basic and translational applications. Here we report the development of two novel DREADD agonists, JHU37152 and JHU37160, and the first dedicated 18F positron emission tomography (PET) DREADD radiotracer, [18F]JHU37107. We show that JHU37152 and JHU37160 exhibit high in vivo DREADD potency. [18F]JHU37107 combined with PET allows for DREADD detection in locally-targeted neurons, and at their long-range projections, enabling noninvasive and longitudinal neuronal projection mapping.",
author = "Jordi Bonaventura and Eldridge, {Mark A.G.} and Feng Hu and Gomez, {Juan L.} and Marta Sanchez-Soto and Abramyan, {Ara M.} and Sherry Lam and Boehm, {Matthew A.} and Christina Ruiz and Farrell, {Mitchell R.} and Andrea Moreno and {Galal Faress}, {Islam Mustafa} and Niels Andersen and Lin, {John Y.} and Ruin Moaddel and Morris, {Patrick J.} and Lei Shi and Sibley, {David R.} and Mahler, {Stephen V.} and Sadegh Nabavi and Pomper, {Martin G.} and Antonello Bonci and Horti, {Andrew G.} and Richmond, {Barry J.} and Michael Michaelides",
year = "2019",
month = dec,
day = "1",
doi = "10.1038/s41467-019-12236-z",
language = "English",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - High-potency ligands for DREADD imaging and activation in rodents and monkeys

AU - Bonaventura, Jordi

AU - Eldridge, Mark A.G.

AU - Hu, Feng

AU - Gomez, Juan L.

AU - Sanchez-Soto, Marta

AU - Abramyan, Ara M.

AU - Lam, Sherry

AU - Boehm, Matthew A.

AU - Ruiz, Christina

AU - Farrell, Mitchell R.

AU - Moreno, Andrea

AU - Galal Faress, Islam Mustafa

AU - Andersen, Niels

AU - Lin, John Y.

AU - Moaddel, Ruin

AU - Morris, Patrick J.

AU - Shi, Lei

AU - Sibley, David R.

AU - Mahler, Stephen V.

AU - Nabavi, Sadegh

AU - Pomper, Martin G.

AU - Bonci, Antonello

AU - Horti, Andrew G.

AU - Richmond, Barry J.

AU - Michaelides, Michael

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a popular chemogenetic technology for manipulation of neuronal activity in uninstrumented awake animals with potential for human applications as well. The prototypical DREADD agonist clozapine N-oxide (CNO) lacks brain entry and converts to clozapine, making it difficult to apply in basic and translational applications. Here we report the development of two novel DREADD agonists, JHU37152 and JHU37160, and the first dedicated 18F positron emission tomography (PET) DREADD radiotracer, [18F]JHU37107. We show that JHU37152 and JHU37160 exhibit high in vivo DREADD potency. [18F]JHU37107 combined with PET allows for DREADD detection in locally-targeted neurons, and at their long-range projections, enabling noninvasive and longitudinal neuronal projection mapping.

AB - Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a popular chemogenetic technology for manipulation of neuronal activity in uninstrumented awake animals with potential for human applications as well. The prototypical DREADD agonist clozapine N-oxide (CNO) lacks brain entry and converts to clozapine, making it difficult to apply in basic and translational applications. Here we report the development of two novel DREADD agonists, JHU37152 and JHU37160, and the first dedicated 18F positron emission tomography (PET) DREADD radiotracer, [18F]JHU37107. We show that JHU37152 and JHU37160 exhibit high in vivo DREADD potency. [18F]JHU37107 combined with PET allows for DREADD detection in locally-targeted neurons, and at their long-range projections, enabling noninvasive and longitudinal neuronal projection mapping.

UR - http://www.scopus.com/inward/record.url?scp=85073152110&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-12236-z

DO - 10.1038/s41467-019-12236-z

M3 - Journal article

C2 - 31604917

AN - SCOPUS:85073152110

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4627

ER -